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Abstract
Background: There is a high prevalence of potentially inappropriate prescriptions in primary care. This is associated
with more frequent adverse events, lower quality of life and more frequent visits to hospital accident & emergency
departments. The aim of the present study is to summarise available evidence on the effectiveness of
deprescription interventions in primary care, and to describe the barriers and enablers of the process from the
point of view of patients and healthcare professionals.
Methods: We designed an umbrella review which includes nine systematic reviews. More than 50% of included
studies were performed with adults in primary care. Two reviewers independently performed data extraction and
analysis.
Results: In considering studies of the effectiveness of interventions, it can be observed that the educational
component of deprescription procedures is a key factor, whilst procedures tailored towards the patient’s situation
offer better results. With regards to studies involving healthcare professionals, the main explored areas were the
balance between risks and benefits, and the need to improve communication with patients as well as other
colleagues involved in patient care. Amongst the identified barriers we found lack of time, inability to access all
information, being stuck in a routine, resistance to change and a lack of willingness to question the prescription
decisions made by healthcare colleagues. With regards to patients, it is clear that they have worries and doubts. In
order to overcome these issues, a good relationship with healthcare professionals and receipt of their support is
required during the process.
Conclusions: Optimizing medication through targeted deprescribing is an important part of managing chronic
conditions, avoiding adverse effects and improving outcomes. The majority of deprescription interventions in
primary care are effective. Good communication between healthcare professionals is a key element for success in
the deprescription process.
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Background
According to the literature, it has been estimated that
polypharmacy affects 30% of individuals aged over 65.
Polypharmacy is quantitatively defined as the use of sev-
eral drugs (usually > 4). In qualitative terms, it refers to
the inappropriate use of drugs or use of not clinically indi-
cated drugs [1, 2]. Thus, potentially inappropriate medi-
cines (PIM) are seen to exist amongst different procedures
or health technologies. These are estimated to be used by
11.5–62.5% of the elderly population [3, 4]. Polypharmacy
and the use of PIM have been associated with more
frequent adverse events, lower quality of life and more fre-
quent visits to hospital accident & emergency departments
[5–9]. Polypharmacy and PIM expose patients to unneces-
sary risks and, therefore, efforts to find effective methods
for reducing their use should be addressed. A great variety
of factors are associated with the discontinuation of treat-
ment such as patient characteristics, patient or care-giver
choices, medication-related factors (eg, duration of action,
risk–benefit profile, etc.) and practitioner-related or health
system-related factors [10].
It is worth noting that the high prevalence of poly-
pharmacy, PIMs and other factors has increased the
focus on desprescribing as a separate entity in research
and practice [11]. In this regard, and according to the re-
view by Reeve et al. [12], deprescription can be defined
as the process of withdrawing an inappropriate medi-
cine, under medical supervision, in order to control
polypharmacy and improve outcomes.
The strategies described to examine desprescribing in-
clude complete reviews of medication, educational inter-
ventions and audits of prescription practices. These
interventions have shown some benefits, such as reduced
polypharmacy, PIM and costs associated with drug use
[13]. Notably, the systematic review conducted by Luc-
chetti concluded that the most commonly identified
PIM prescribed to elderly patients were benzodiazepines,
non-steroidal anti-inflammatory drugs (NSAID), antihis-
tamines and antipsychotic drugs [14].
To understand the effectiveness of deprescription
interventions, in addition to identifying barriers and
enablers to the deprescription process, we performed
an umbrella review of the evidence produced by a
number of published systematic reviews. In this way,
we summarised the evidence of studies assessing non-
pharmacological and pharmacological interventions
for deprescription in primary care. Further, we
described the barriers and enablers of the deprescrip-
tion process from the patients’ and healthcare profes-
sionals’ point of view.
Methods
An umbrella review of existing systematic reviews was
undertaken [15]. The databases consulted were PubMed,
Scopus, Embase and The Cochrane Library. This was com-
plemented by searches in the following resources: Google
Scholar and the Spanish Network of Agencies for Health
Technology Assessment (www.redets.msssi.gob.es/). In
addition to this, references in the documents previously
identified were reviewed. The search strategy was tailored
to the different databases and validated by a librarian who
specialised in public health (Additional file 1: Appendix 1).
The search was updated in March 2019.
Systematic reviews were included which considered
studies that involved programmes or interventions deliv-
ered to adults. All reviews had the aim of evaluating
deprescribing of one or more regular medication pre-
scriptions by a health professional. Furthermore, system-
atic reviews that synthesised opinions and beliefs of
health professionals or patients about the deprescription
process by were also included. We excluded reviews in
which > 50% of the included studies were not performed
in primary care and were written in languages other than
English or Spanish. Included reviews were restricted to
primary care, since individuals in institutions, residences
or recently discharged from hospital may present widely
differing factors (their environment, frailty, nature and
number of illnesses and treatment goals). No restrictions
were applied based on date of publication. Additional file 1:
Appendix 2 contains a more detailed explanation of the
stages and methods used in this review.
Data extraction and analysis: two reviewers independ-
ently assessed the titles and abstracts to determine
whether documents met the inclusion criteria. Those
meeting criteria were kept as potential documents (first
round of selection). In the second round of selection, three
reviewers (AOL, JMM and AMH) independently assessed
the full texts of selected documents. In both rounds of se-
lection, any disagreements between reviewers were settled
by another reviewer (CBT and AMM) through consensus.
A data extraction sheet was designed and, where neces-
sary, authors of reviews were contacted to clarify any
doubts which arose. To ensure that the meaning or
breadth of data was not changed, particularly in regards to
qualitative studies, results were extracted following con-
sensus of the entire team (AOL, AMH, CBT, JMM, AMM
and independent staff) (Additional file 1: Appendix 2).
The writing process of this umbrella revision was under-
taken according to an adapted version of the guide pub-
lished by Bougioukas [16] (AOL and CBT). Only data on
deprescription or data coming from the primary care set-
ting was extracted where possible. Mendeley reference li-
brary management software was used for this purpose.
Results
Selection of studies and features of reviews
The initial search identified 888 articles. Of these, 734
documents were excluded following a subsequent reading
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of titles and abstracts. The main reasons for exclusion
were that the articles did not report a review study, or that
they focused on prevalence, instead of aspects relating to
the research question. After reading the full texts of arti-
cles, a total of 9 reviews were included in the definitive
summary (Table 1), six of which addressed barriers and
enablers, whilst the other three explored the effectiveness
of interventions (Tables 2 and 3).
Effectiveness of deprescription interventions
Three systematic reviews were included to accomplish
the aim of assessing the effectiveness of interventions.
The first of them analysed health outcomes amongst pa-
tients aged over 65 years old and the nature of the
deprescription process for one or more drugs under-
taken by a physician [17]. This review included 116 arti-
cles but, although 73 of them (62.9%) were carried out
in primary care, they did not conduct any specific ana-
lyses. Clinical trials on polypharmacy revealed no signifi-
cant differences in mortality (OR 0.82; 95% CI 0.61–
1.11, I2 23%; 10 studies, participants = 3151). Mortality
analysis based on intervention type revealed that inter-
ventions tailored to patients’ specific situations showed a
significant decrease in mortality (OR = 0.62; 95% CI
0.43–0.88, I2 0%; 8 studies, participants = 1906). In con-
trast, interventions based on education programmes evi-
denced no change in mortality rates (OR = 1.21; 95% CI
0.86–1.69, I2 0%; 2 studies, participants = 1245). There
were no differences based on patient’s age. This was the
case for patients older than 80 years (OR = 0.88; 95% CI
0.58–1.34; I2 36%; 7 studies, participants = 1923) and for
patients aged between 65 and 79 years (OR = 0.64; 95%
CI 0.40–1.04; I2 0%; 3 studies, participants = 1228). In
addition, there were no significant differences in mortal-
ity in either randomized studies (OR 0.59; 95% CI 0.33–
1.07; I2 0%; 5 studies, participants = 453) or non-
randomized studies (p = 0.81) with single medications/
classes. In polypharmacy interventions, deprescription
did not cause significant changes in adverse events due
to withdrawal, incidence of adverse events, cognitive
function, having a fall, or quality of life. Lastly, interven-
tions reduced the number of consumed drugs (MD
-0.99; 95% CI − 1.83 to − 0.14; 2 studies, participants =
451), as well as the consumption of potentially inappro-
priate medicines (MD -0.49; 95% CI − 0.70 to − 0.28; 3
studies, participants = 839). For interventions on a spe-
cific drug, no significant differences were observed either
in quality of life, or in events caused by medicine with-
drawal such as a worsening of the condition with differ-
ent medicines such as benzodiazepines, glucosamine,
carbamazepine, corticoids, etc [17].
Another systematic review evaluated the impact of
deprescription interventions and considered the follow-
ing outcomes: medication load, chronic condition
management and mental disorders [20]. Regarding the
methods used to assess the deprescription intervention,
it was found that interventions with more effective
deprescription outcomes were performed by clinicians
intensively (showing success in both studies). On the
other hand, success was also seen in other studies based
on recommending specific medications to patients (suc-
cess in 4 of 5 studies). Mixed interventions were also
successful (educational component with specific medica-
tion interventions for high-risk patients) in four of six
studies. In this review, some adverse effects of depre-
scription were identified such as the unmasking of heart
failure in diuretics and increases in vertebral fracture in
the removal of bisphosphonates.
Further, a review by Hansen et al. [19] evaluated the
effectiveness of interventions based on behavioural
change techniques. In this way, a meta-analysis including
11 studies found a significant reduction in the average
number of prescribed medications − 0.74 (CI 95% -1.26;
− 0.22). This result is similar to those found when ana-
lysing the 9 studies conducted in primary care − 0,80 (CI
95% -1.40; − 0.21), although these analyses showed sig-
nificant heterogeneity (p < 0.0001).
One systematic review was focused on the deprescrip-
tion of benzodiazepines (BZD) and Z class hypnotics
amongst the elderly (> 65 years old) [18]. This review in-
cluded a total of 7 studies, 4 of which were carried out
in primary care. The first of the primary care studies
was a crossover clinical trial in which the intervention
involved pharmacological substitution with melatonin
and a placebo was administered to 56 patients. The use
of melatonin was found to improve quality of sleep (p =
0.025), symptoms of depression (p = 0.043) and anxiety
(p = 0.009). Other primary care studies have used mixed
methods. In two of these studies patients were given
education sessions, informed about harm linked to long-
term use of hypnotic drugs and given recommendations
on how to reduce BZD use. Further, consumption of
benzodiazepines was found to decrease by 27–36%,
whilst consumption in the control groups increased by 5
and 4%, respectively. The last of these studies used psy-
chological support to reduce drug doses (n = 138), with
80% of patients stopping their treatment after 6 months.
Moreover, this study showed an improvement in quality
of life (p < 0.005) and social skills, although no signifi-
cant differences were found in sleep quality, cognitive or
psychomotor function, mood and symptoms.
Another review focused on deprescription of proton
pump inhibitors (PPI) in older adults (≥65 years) and in-
cluded a total of 21 studies. Interventions were proved
to be effective in 6 studies, with 11 being inconclusive
and 4 concluding that intervention had been ineffective
[21]. With regards to effective interventions, 4 were car-
ried out in primary care with all of these having an
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educational component, 2 used information leaflets and
2 delivered 30-min educational sessions. In the interven-
tions that used leaflets, a significant reduction was ob-
served both in mean dosage and in the number of
patients taking low-dose PPI. The other 2 interventions
showed a significant reduction in the risk of continuing
to receive potentially inappropriate medicine, both after
12 months (OR 0.40; 95% CI 0.17–0.94) and after 4–6
months (OR 0.30; 95% CI 0.14–0.68; p = 0.04). As for
the articles reporting inconclusive or ineffective
interventions, these referred to two clinical trials carried
out in primary care. The first of these determined effi-
cacy of the intervention based on a personalized guide
on PPI treatment, prepared by a specialist practitioner
and containing instructions for general practitioners
(GPs). This study showed that practitioners who re-
ceived this guide took more action than those who were
in the control group, although differences were not sig-
nificant (p = 0.07). The other study assessed the effect-
iveness of conducting a medication review and preparing
an action plan in pharmacists. Although a decrease in
the number of inappropriate PPI was observed, differ-
ences were not significant (p = 0.10). Lastly, it is note-
worthy that the remaining articles about primary care
included in this review did not conduct any statistical
analysis of data.
Barriers and enablers in the deprescription process
according to medical practitioners
We included two reviews in this regard, one on PIM and
the other on benzodiazepines and Z class hypnotics. The
review on PIM deprescription included 21 articles rele-
vant to older adults (≥65 years), of which 18 were carried
out in primary care (85.7%) [23]. Poor perceptions held
Table 2 Main domains identified in the reviews regarding the
practices and perceptions of other health professionals
Anderson (2014) [23]
Awareness: level of insight a prescriber has into the appropriateness
of his/her prescribing.
Inertia: failure to act despite awareness that prescribing is potentially
inappropriate. This was due to the perception that ceasing PIMs was
a less appealing proposition than continuing PIMs.
Self-Efficacy: factors that influence a prescriber’s belief and
confidence in his or her ability to address PIM use, involving
knowledge, skills, attitudes, influencers, information and support for
decision making.
Feasibility: factors that are external to the prescriber and determine
the ease or likelihood of change. They relate to patient characteristics,
resource availability, work practices, medical and societal health
beliefs and culture, and regulations.
Sirdfield (2013) [22]
The changing context of benzodiacepines prescribing: norms of
practice, evidence, guidance, introduction of new drugs and services,
legal regulatory frameworks and societal attitudes around the
treatment of conditions.
Role and responsibility of general practice: Balance between
responsibility over historical prescribing practices (help patient) and
the responsibility to minimize benzodiacepine use.
The ‘deserving’ patient: GPs often managed the tension between
minimizing prescribing and their responsibility to help patients on a
case-by-case basis. They needed to justify giving or withholding ben-
zodiazepines, expressed in the literature through the concept of the
‘deserving patient.
Perceived patient expectations Prescribing was influenced by how
doctors perceived patients’ expectations, motivations and ability to
cope.
GP attitudes towards different interventions Treatment choices of
GPs in response to their perceptions of their patients, their patients’
expectations, and their own role and responsibilities were further
influenced by their own attitudes and beliefs about different
interventions.
Different challenges for managing initiation and withdrawal GPs’
view of their role, perceived risks and effectiveness of
benzodiazepines or alternative treatments, and the patient all
influenced whether or not a GP chose to initiate, continue or
withdraw benzodiazepines.
Ambivalent attitudes towards prescribing benzodiazepines
leading to inconsistent strategies for managing prescribing This
attitude ranged from those who rarely prescribed, to those who did
not see a problem with prescribing benzodiazepines. For most GPs,
located in the middle of this continuum, these were complex
decisions leading to conflicting pressures about whether or not to
prescribe.
Table 3 Main domains identified in included reviews of patient
perceptions
Reeve (2013) [24]
Appropriateness Dis/agreement with the appropriateness of
cessation. Barrier: Experience and fear of side effects, lack of efficacy,
fear of addiction/dependency, etc. Enablers: lack of effectiveness,
experience of side effects, fear of addiction.
Process: Barrier: lack of time or support. Enablers: Knowledge that
they could restart medication, follow-up/primary care physician sup-
port available, physician support (time spent)
Influences: individuals/events that could influence patients’ decisions
to cease medication.
Fear: Barrier: fear of cessation (worsening condition, withdrawal
reaction, etc.).
Dislike: Enablers: the inconvenience of taking medication, cost of
purchasing, etc.
Sirdifield (2017) [25]
Patient’s negative perceptions of insomnia and its impact:
perceptions of insomnia, consequences, etc.
Failed self-care strategies: patients cope with their problems in
other ways (distract themselves, lifestyle changes,…)
Triggers to medical help-seeking: medical consultations were
triggered by significant life events
Attitudes towards treatment options and service provision: what
patients wanted/expected from health professionals.
Varying patterns of use: Although the majority of patients take
medicine as prescribed, some of them minimize its use.
Withdrawal: Withdrawal strategies
Reason for initial or ongoing use: the medication was effective in
the first instance.
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by prescribing physicians of prescription appropriateness
was shown to be a barrier, concluding that it is necessary
for prescriptions at a population level to be translated
into prescription practices at an individual level. Add-
itionally, another considered barrier was the perception
that it may be of more value to continue PIM treatment
rather than suspend it, even though such treatment
could be inappropriate. Barriers were identified relating
to the consequences of deprescription for prescribers
(increased burden of care, conflicts with colleagues, re-
duced credibility, etc.), patients (withdrawal symptoms,
worsening of the event/condition that triggered treat-
ment in the first place, etc.) and other professionals
(increased workload, etc.). In contrast, taking the ben-
efits of deprescription into consideration is an en-
abler. Thus, underestimating the adverse effects of
medicines was identified as a barrier, particularly in
the case of psychoactive drugs. Another identified
barrier was delegating the responsibility for depre-
scription to another professional.
In this regard, having better information about the
risk-benefit ratio, greater confidence to cease treatment,
and more experience and training were identified as en-
ablers for deprescription. Gaps in knowledge and skills
led to poor communication between the different health-
care professionals involved in patient care (inadequate
transfer, fragmented information, etc.). This barrier is
closely linked to complaints voiced by healthcare profes-
sionals in relation to lack of time and not being able to
access all the information required. In this respect, pres-
sure to comply with the recommendations of clinical
practice guidelines and the routine effect of prescription
are negatively perceived by professionals. Moreover, with
regards to the feasibility of change, the main barriers
mentioned were resistance or ambivalence of patients to
change and their refusal to try alternatives. In terms of
resources, the most commonly found limitation was lack
of time and effort to review/cease medication, followed
by the limited availability of alternatives. Another per-
ceived enabler was access to support services (mental
health workers and pharmacists) in order to review med-
ical prescriptions. Feelings of discomfort and reluctance
to question the prescription decisions made by a col-
league (resulting in repeated prescription) were linked to
medical and social beliefs. Such responses came out of
respect for professional independence or the medical
hierarchy. Lastly, externally imposed quality guidelines
such as prescription thresholds (for example, restricted
access, cost, etc.) and monitoring by the prescription au-
thorities are also perceived as barriers. Greater dialogue
with patients increases patient’s understanding and facil-
itates shared decision making [23].
The review of benzodiazepines and Z class hypnotics
included 8 studies which analysed general practice and
nurse experiences [22]. Although primary care practi-
tioners valued being better informed about risks, the his-
torical culture of optimism regarding benefits and
ingenuity regarding risks, has been replaced by a more
sceptical attitude which could be a barrier for depre-
scription. Physicians mentioned treating more patients,
including those with mental morbidity, who used to be
treated in specialised care. Whilst GPs generally feel re-
sponsible for these inappropriate prescriptions, different
attitudes are observed regarding historical prescriptions.
It must be pointed out that the conditions for prescrib-
ing benzodiazepines and for other interventions, includ-
ing deprescription, are dictated by patient characteristics
such as their age, drug abuse, complexity, etc... However,
these circumstances are conditioned by the practitioner’s
knowledge or empathy with the patient’s situation.
Other mentioned factors include lack of time, possible
patient dissatisfaction and concern that patients may
change their GP, all of which complicates deprescription
of these medicines.
With regards to the types of strategies used for man-
aging the prescription of benzodiazepines, a wide variety
of situations can be considered. Three main situations
are described: practitioners prefer short-term, low-dose
prescriptions and warn their patient about potential ad-
verse effects; practitioners consider patient demedication
as part of their remit; and practitioners who tacitly and
explicitly rule out benzodiazepine use (Table 2).
Barriers and enablers in the deprescription process
according to patients
A review by Reeve et al. included 21 studies (1310 par-
ticipants) [24] and described the barriers and enablers
that may influence patient’s decisions to cease medica-
tion. The most frequently mentioned aspect in relation
to barriers is appropriateness. In this sense, patients
question the withdrawal of their medication, arguing
that they experienced improvement when treatment
began and, even if this improvement does not continue,
they hope that it will benefit them in the future. More-
over, failure when using other alternatives was described
in this study. Furthermore, lack of support, and lack of
time and opportunity for discussion with the primary
care physician was mentioned as a difficulty before and
after deprescription. The fact that patients and physi-
cians have a good relationship results in a positive influ-
ence of GPs on the cessation of treatment, whilst also
encouraging GP support for increasing patient’s dispos-
ition towards leaving treatment. Similarly, the fact that
their medical practitioner continues to prescribe is per-
ceived as an indication that continued treatment is ne-
cessary. Most of the included studies refer to non-
specific fears such as “worrying about the negative con-
sequences of treatment withdrawal”, “seeing treatment
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withdrawal as problematic” and “being unsure of one’s
ability to cope with it”. Other expressed fears were con-
cerns that the disease may worsen or experiences of de-
pendency syndromes.
Deprescription enablers were found in the case of pa-
tients who felt that they no longer needed to take their
medication, questioned it, found it ineffective or were
concerned about its adverse effects. Another deprescrip-
tion enabler (or enabler of reduced dosage) was knowing
that, if necessary (e.g. symptoms reappear), individuals
could start taking the medication again and knew that
they could count on the support of medical and other
services. A good patient-physician relationship, the
media and publication of new evidence were identified
as positive influences. The inconvenience of taking med-
icines (number of tablets or injections each day), in
addition to the cost, were mentioned as reasons to stop
taking them. In addition, patients expressed psycho-
logical benefits of stopping to take medication, reporting
having more control over their lives and liking them-
selves better when not on medication [25] (Table 3).
Discussion
To the extent of our knowledge, this umbrella review
was the first attempt to provide a general overview of
the deprescription process in primary care, taking into
consideration both the efficacy of interventions, along-
side barriers and enablers of the deprescription process.
The articles reviewed showed that deprescription in clin-
ical practice was feasible and reduces the quantity of
both medicines and PIM use [26]. Additionally, knowledge
of relevant barriers and enablers allows better implemen-
tation of interventions for deprescribing medicines. Most
of the included reviews showed that communication and
support amongst healthcare professionals are proved to be
key elements for optimising the deprescription process.
In this respect, we have to take into account that the
benzodiazepine group, both anxiolytic (A) and hypnotic
(H) drugs alike, is one of the most prescribed drugs in
the majority of developed countries, with Europe having
the highest mean consumption worldwide [27, 28]. Fur-
thermore, scientific literature states that consumption of
benzodiazepines is linked to an increased risk of acci-
dents, suicide, mortality, dementia, and broken hips [29–
32]. This justifies why 3 of the 7 reviews included in this
study focus on these drugs.
The patient-centred review of benzodiazepines
shows that the adverse effects of medication can
have an effect on the use of these drugs. However,
some patients state that they are willing to pay this
price if it means they will experience improved sleep
quality. The main reasons for deprescription are be-
ing aware of how medication affects patients’ daily
routines and those of the people around them [25].
The deprescription process encourages reflection on a
number of issues [33]. The first is about the appropriate-
ness of treatment (the principle of beneficence), in view
of the negative or neutral risk-benefit ratio of PIM. The
second regards patient safety (the principle of non-
maleficence), in view of the fact that many patients tak-
ing these treatments are exposed to unjustified risks and
adverse effects. The third issue refers to efficiency (the
principle of fairness) and speaks to making a better use
of scarce resources [34]. Furthermore, it must be borne
in mind that prescription decisions are not made in iso-
lation. Indeed, such decisions are taken in careful con-
sideration of a large number of individual factors such as
general state of health, care objectives and compliance
with the current system [35]. In this respect, the litera-
ture uncovers one factor that promotes less-than-
optimal use of health technologies. This factor is inad-
equate communication between physicians and patients.
This lack of communication is linked to false expecta-
tions about benefits and choosing treatments which
might not have been chosen had better information been
available [36].
From the perspective of patient safety, the results of
the present work are of particular relevance. In accord-
ance with an examination of adverse effects in primary
care, one systematic review estimated the prevalence of
medication errors in community environments to fall
between 2 and 94%. This disparity may be due to differ-
ences in definitions, populations, methodologies, etc.
[37]. In Spain, it has been estimated that 48.2% of the
adverse effects identified are related to medication [38,
39]. This phenomenon is particularly relevant in poly-
pharmacy amongst elderly patients [40–42]. In this re-
spect, a systematic review calculated the cost of patient
non-safety and adverse effects in the administration of
medicines. This determined costs of between 469 and
790 million euros annually for medication-related ad-
verse effects, and just over 91 million euros annually for
incorrect medication [43].
An outstanding finding of this review is that interven-
tions tailored to patients’ specific situations produce the
best results for deprescription as they decrease thera-
peutic load [20]. This fact underlines the importance of
focusing interventions to target patient characteristics.
Moreover, these interventions should have multiple
components (advice, communication, ongoing support,
etc.). In this regard, neither protecting patient independ-
ence, nor taking their preferences into account, should
be discarded. Over recent decades, various tools have
been developed that facilitate the identification of in-
appropriate prescription in elderly patients. Examples in-
clude deprescribe.org, which has several tools (including
an app), and provides information for professionals and
patients [44]. Another useful tool is the STOPP criteria
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(Screening Tool of Older Person’s potentially inappro-
priate Prescriptions). This consists of 65 indicators of
potentially inappropriate prescriptions which include
drug-medication and medication-clinical interactions,
therapeutic duplicity and medications that increase the
risk of cognitive impairment and falls in the elderly [45].
Finally, the AGS Beers Criteria is another tool for identi-
fication of inappropriate prescription, although its imple-
mentation in Europe is limited by its lack of applicability
and some other deficiencies [46, 47].
Limitations
This review has some potential limitations which must
be taken into account. There may be a risk of misrepre-
senting incomplete evidence, however, to minimise this,
different databases were consulted. Furthermore, a sys-
tematic search strategy was used to make it more likely
that the included reviews were representative of the
body of systematic reviews available on deprescription
interventions effectiveness. Umbrella reviews can only
report what researchers have investigated, published and
systematically reviewed or meta-analysed [48]. Finally,
although the information extracted was focused on pri-
mary care, some of the included systematic reviews were
applied to other settings in addition to primary care.
Consequently, results pertain to an array of contexts and
patients and, therefore, may not be applicable to some
specific patient populations (e.g. frail older people).
Conclusions
In general, most of the deprescription interventions
carried out in primary care are effective. In addition,
the gathered evidence showed that, in certain cases,
deprescription has benefits for patients. In terms of
barriers and facilitators, good communication between
healthcare professionals was as a key element for suc-
cess in the deprescription processes, with these ele-
ments being similar to those described in other areas
[49]. In the same way, interventions designed to pro-
mote the rational use of medicines should provide in-
formation about the risk-benefit ratio, considering the
possibility that the resultant risks exceed the potential
benefits [50, 51].
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12875-020-01166-1.
Additional file 1: Appendix 1. Complete search strategy by database.
Appendix 2: Investigation stages and methods for umbrella review.
Abbreviations
BZD: Benzodiazepines; 95% CI: 95% confidence intervals; NSAID: Non-





AOL and CBT contributed substantially to the conception, design, analysis,
and interpretation of the data with critical guidance from JMM and MAGV.
AMM assisted AMH with the design of the search strategies. All the authors
have revised the manuscript critically for intellectual content. All authors
have seen and approved the final content and agreed to be accountable for
all aspects of the work.
Funding
This research was financed by “Proyectos de innovación en salud” (PIN-0155-
2017) Andalucía, Spain. The Funder did not influence the study design; data
collection; data analysis, decision to publish, or preparation of the
manuscript. The responsibility for the information and the views set out in
this paper lie entirely with the authors.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
This project received approval from “the regional ethical and research




The authors of this paper state that they have no relevant conflicts of
interest, which may have an effect on study design, analysis or presentation
of results.
Author details
1Andalusian School of Public Health (Spanish acronym EASP), Granada, Spain.
2Instituto de Investigación Biosanitaria ibs, GRANADA, Granada, Spain. 3CIBER
en Epidemiología and Salud Pública (CIBERESP), Madrid, Spain. 4Public Health
Research Group, University of Alicante, Alicante, Spain. 5Faculty of Education
and Social Work, University of Valladolid, Valladolid, Spain. 6GIESA, Applied
Sociocultural Studies (SEJ208), University of Granada, Granada, Spain.
7Farmacia del Puente (Pinos Puente), Granada, Spain. 8Centro Andaluz de
Información del Medicamento (CADIME), Campus Universitario de Cartuja,
Granada, Spain.
Received: 28 January 2020 Accepted: 14 May 2020
References
1. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy:
the process of deprescribing. JAMA Intern Med. 2015;175(5):827–34. https://
doi.org/10.1001/jamainternmed.2015.0324.
2. Revisión de prescripciones para evitar problemas de seguridad. Centro
Andaluz de Documentación e Información de Medicamentos (CADIME).
https://cadime.es/bta/bta-2-0-publicados/367-revisi%C3%B3n-de-
prescripciones-para-evitar-problemas-de-seguridad.html. Accessed 02 Dec
2018.
3. Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K.
Potentially inappropriate prescribing in community-dwelling older people
across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;
71(12):1415–27. https://doi.org/10.1007/s00228-015-1954-4.
4. Guaraldo L, Cano G, Damasceno S, Rozenfeld S. Inappropriate medication
use among the elderly: a systematic review of administrative databases.
BMC Geriatr. 2011;11:79. https://doi.org/10.1186/1471-2318-11-79.
5. Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing
and adverse health outcomes in community dwelling older patients. Br J
Clin Pharmacol. 2014;77(1):201–10. https://doi.org/10.1111/bcp.12161.
6. Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of potentially
inappropriate prescribing on adverse drug events, health related quality of
life and emergency hospital attendance in older people attending general
practice: a prospective cohort study. J Gerontol A Biol Sci Med Sci. 2017;
72(2):271–7. https://doi.org/10.1093/gerona/glw140.
Olry de Labry Lima et al. BMC Family Practice          (2020) 21:100 Page 10 of 12
7. Muhlack DC, Hoppe LK, Weberpals J, Brenner H, Schöttker B. The
Association of Potentially Inappropriate Medication at older age with
cardiovascular events and overall mortality: a systematic review and meta-
analysis of cohort studies. J Am Med Dir Assoc. 2017;18(3):211–20. https://
doi.org/10.1016/j.jamda.2016.11.025.
8. Wauters M, Elseviers M, Vaes B, et al. Too many, too few, or too unsafe?
Impact of inappropriate prescribing on mortality, and hospitalization in a
cohort of community-dwelling oldest old. Br J Clin Pharmacol. 2016;82(5):
1382–92. https://doi.org/10.1111/bcp.13055.
9. Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials:
methods to reduce polypharmacy and the impact on prescribing and
clinical outcomes. Clin Geriatr Med. 2012;28(2):237–53. https://doi.org/10.
1016/j.cger.2012.01.006.
10. Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication
discontinuation in patients with attention-deficit/hyperactivity disorder - a
systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543–69.
https://doi.org/10.2147/NDT.S65721.
11. Gnjidic D, Le Couteur DG, Hilmer SN. Discontinuing drug treatments. BMJ.
2014;349:g7013. https://doi.org/10.1136/bmj.g7013.
12. Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging
definition of “deprescribing” with network analysis: implications for future
research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–68.
https://doi.org/10.1111/bcp.12732.
13. Farrell B, Pottie K, Rojas-Fernandez CH, Bjerre LM, Thompson W, Welch V.
Methodology for developing deprescribing guidelines: using evidence and
GRADE to guide recommendations for deprescribing. PLoS One. 2016;11(8):
e0161248. https://doi.org/10.1371/journal.pone.0161248.
14. Lucchetti G, Lucchetti ALG. Inappropriate prescribing in older persons: a
systematic review of medications available in different criteria. Arch
Gerontol Geriatr. 2017;68:55–61.
15. Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a
systematic review of systematic reviews of healthcare interventions. BMC
Med Res Methodol. 2011;11(1):15. https://doi.org/10.1186/1471-2288-11-15.
16. Bougioukas KI, Liakos A, Tsapas A, Ntzani E, Haidich A-B. Preferred reporting
items for overviews of systematic reviews including harms checklist: a pilot
tool to be used for balanced reporting of benefits and harms. J Clin
Epidemiol. 2018;93:9–24. https://doi.org/10.1016/j.jclinepi.2017.10.002.
17. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility
and effect of deprescribing in older adults on mortality and health: a
systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:583–623.
https://doi.org/10.1111/bcp.12975.
18. Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review
of interventions to deprescribe benzodiazepines and other hypnotics
among older people. Eur J Clin Pharmacol. 2017;73(8):927–35. https://doi.
org/10.1007/s00228-017-2257-8.
19. Hansen CR, O’Mahony D, Kearney PM, et al. Identification of behaviour
change techniques in deprescribing interventions: a systematic review and
meta-analysis. Br J Clin Pharmacol. 2018;84(12):2716–28. https://doi.org/10.
1111/bcp.13742.
20. Dills H, Shah K, Messinger-Rapport B, Bradford K, Syed Q. Deprescribing
Medications for Chronic Diseases Management in Primary Care Settings: A
Systematic Review of Randomized Controlled Trials. J Am Med Dir Assoc.
2018;19(11):923–935.e2. https://doi.org/10.1016/j.jamda.2018.06.021.
21. Wilsdon T, Hendrix I, Thynne T, Mangoni AA. Effectiveness of interventions
to deprescribe inappropriate proton pump inhibitors in older adults. Drugs
Aging. 2017;34(4):265–87. https://doi.org/10.1007/s40266-017-0442-1.
22. Sirdifield C, Anthierens S, Creupelandt H, Chipchase SY, Christiaens T,
Siriwardena AN. General practitioners’ experiences and perceptions of
benzodiazepine prescribing: systematic review and meta-synthesis. BMC
Fam Pract. 2013;14:191. https://doi.org/10.1186/1471-2296-14-191.
23. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and
enablers to minimising potentially inappropriate medications in adults: a
systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544.
https://doi.org/10.1136/bmjopen-2014-006544.
24. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to
and enablers of deprescribing: a systematic review. Drugs Aging. 2013;
30(10):793–807. https://doi.org/10.1007/s40266-013-0106-8.
25. Sirdifield C, Chipchase S, Owen S, Siriwardena A. A systematic review and
meta-synthesis of patients’ experiences and perceptions of seeking and
using benzodiazepines and Z-drugs: towards safer prescribing. Patient. 2017;
10(1):1–15. https://doi.org/10.1007/s40271-016-0182-z.
26. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications
to combat polypharmacy. Ther Adv drug Saf. 2015;6(6):212–33. https://doi.
org/10.1177/2042098615613984.
27. Garcia MAF, Olry de Labry Lima A, Ferrer Lopez I, Bermudez-Tamayo C.
Analysis of changes in trends in the consumption rates of benzodiazepines
and benzodiazepine-related drugs. J Pharm policy Pract. 2018;11:1. https://
doi.org/10.1186/s40545-017-0128-4.
28. Sanz EJ, Castresana C, Laguna L, Garc J, Espa A. Uso de Benzodiazepinas en
España. Aemps; 2006.
29. Requena G, Huerta C, Gardarsdottir H, et al. Hip/femur fractures associated
with the use of benzodiazepines (anxiolytics, hypnotics and related drugs):
a methodological approach to assess consistencies across databases from
the PROTECT-EU project. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):66–
78. https://doi.org/10.1002/pds.3816.
30. Smink BE, Egberts ACG, Lusthof KJ, Uges DRA, de Gier JJ. The relationship
between benzodiazepine use and traffic accidents: a systematic literature
review. CNS Drugs. 2010;24(8):639–53. https://doi.org/10.2165/11533170-
000000000-00000.
31. Bellou V, Belbasis L, Tzoulaki I, Middleton LT, Ioannidis JPA, Evangelou E.
Systematic evaluation of the associations between environmental risk
factors and dementia: an umbrella review of systematic reviews and meta-
analyses. Alzheimers Dement. 2016. https://doi.org/10.1016/j.jalz.2016.07.152.
32. Dodds TJ. Prescribed Benzodiazepines and Suicide Risk: A Review of the
Literature. Prim care companion CNS Disord. 2017;19(2). https://doi.org/10.
4088/PCC.16r02037.
33. Avery AJ, Bell BG. Rationalising medications through deprescribing. BMJ.
2019;364:l570. https://doi.org/10.1136/bmj.l570.
34. Puyol A. Ethics, equity and social determinants of health. Gac Sanit. 2012;
26(2):178–81. https://doi.org/10.1016/j.gaceta.2011.08.007.
35. Kaur S, Mitchell G, Vitetta L, Roberts MS. Interventions that can reduce
inappropriate prescribing in the elderly: a systematic review. Drugs Aging.
2009;26(12):1013–28. https://doi.org/10.2165/11318890-000000000-00000.
36. Green AR, Tung M, Segal JB. Older adults’ perceptions of the causes and
consequences of healthcare overuse: a qualitative study. J Gen Intern Med.
2018. https://doi.org/10.1007/s11606-017-4264-y.
37. Assiri GA, Shebl NA, Mahmoud MA, et al. What is the epidemiology of
medication errors, error-related adverse events and risk factors for errors in
adults managed in community care contexts? A systematic review of the
international literature. BMJ Open. 2018;8(5):e019101. https://doi.org/10.
1136/bmjopen-2017-019101.
38. Aranaz-Andrés JM, Aibar C, Limón R, et al. A study of the prevalence of
adverse events in primary healthcare in Spain. Eur J Pub Health. 2012;22(6):
921–5. https://doi.org/10.1093/eurpub/ckr168.
39. Mira JJ, Carrillo I, Lorenzo S, et al. The aftermath of adverse events in
Spanish primary care and hospital health professionals. BMC Health Serv
Res. 2015;15(1):151. https://doi.org/10.1186/s12913-015-0790-7.
40. Assiri GA, Grant L, Aljadhey H, Sheikh A. Investigating the epidemiology of
medication errors and error-related adverse drug events (ADEs) in primary
care, ambulatory care and home settings: a systematic review protocol. BMJ
Open. 2016;6(8) http://bmjopen.bmj.com/content/6/8/e010675.abstract.
41. Tache SV, Sonnichsen A, Ashcroft DM. Prevalence of adverse drug events in
ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7–8):977–
89. https://doi.org/10.1345/aph.1P627.
42. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A.
Systematic review of the incidence and characteristics of preventable
adverse drug events in ambulatory care. Ann Pharmacother. 2007;41(9):
1411–26. https://doi.org/10.1345/aph.1H658.
43. Antoñanzas VF. Aproximación a los costes de la no seguridad en el Sistema
Nacional de Salud. Rev Esp Salud Publica. 2013;87(3):283–92.
44. Farrell B TC. Deprescribing. https://deprescribing.org. Accessed 9 Apr 2019.
45. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (screening tool
of older person’s prescriptions) and START (screening tool to alert doctors
to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;
46(2):72–83.
46. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially
inappropriate prescribing and cost outcomes for older people: a national
population study. Br J Clin Pharmacol. 2010;69(5):543–52. https://doi.org/10.
1111/j.1365-2125.2010.03628.x.
47. Delgado ES, Muñoz MG, Montero BE, Sánchez CC, Gallagher PF, Cruz-Jentoft
AJ. Inappropriate prescription in older patients: the STOPP/START criteria.
Rev Esp Geriatr Gerontol. 2009;44(5):273–9.
Olry de Labry Lima et al. BMC Family Practice          (2020) 21:100 Page 11 of 12
48. Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid
Based Ment Heal. 2018;21(3):95 LP–100. https://doi.org/10.1136/ebmental-
2018-300014.
49. Paque K, Vander Stichele R, Elseviers M, et al. Barriers and enablers to
deprescribing in people with a life-limiting disease: a systematic review.
Palliat Med. 2019;33(1):37–48. https://doi.org/10.1177/0269216318801124.
50. Carmona JH, Cruz IA, Ruiz FP. Un modelo de deprescripción prudente. Med
Clin (Barc). 2014;144(8):362–9. https://doi.org/10.1016/j.medcli.2014.02.026.
51. Reeve E, Denig P, Hilmer SN, ter Meulen R. The ethics of deprescribing in
older adults. J Bioeth Inq. 2016;13(4):581–90. https://doi.org/10.1007/s11673-
016-9736-y.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Olry de Labry Lima et al. BMC Family Practice          (2020) 21:100 Page 12 of 12
